Key Highlights of the Report: New pathogens and rising rates for multidrug-resistant (MDR) treatable infections guarantee the need for new antibiotics and therapeutics. For new antibiotics, other treatments, and quick diagnostic systems, pharmaceutical and biotechnology businesses are spending on research and development. There is an increasing emphasis placed on the creation of products for...